Nilotinib: A novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias

Elias Jabbour, Samih El Ahdab, Jorge Cortes, Hagop Kantarjian

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Fingerprint Dive into the research topics of 'Nilotinib: A novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias'. Together they form a unique fingerprint.

Medicine & Life Sciences